OTC · Biotechnology

Actinogen Medical Limited (ATGGF) Stock

$0.00 OTC: ATGGF Healthcare

Actinogen Medical Limited is an Australian biotechnology firm specializing in the creation of treatments for neurological and neuropsychiatric conditions linked to abnormal brain cortisol levels. Their primary therapeutic candidate, Xanamem, functions as an inhibitor of the 11ß-HSD1 enzyme.

Valuation

MetricValue
Price$0.00
Market Cap$2.97M
P/E Ratio-7.07
P/B Ratio0.38
P/S Ratio0.40
EPS (TTM)$0.00
52-Week High$0.04
52-Week Low$0.00
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-110.77%
ROA-63.83%
ROCE-235.63%
Gross Margin100.00%
Operating Margin-608.64%
Net Margin-243.22%
Debt/Equity0.03
Current Ratio4.19

Annual Financials (USD)

Metric20212022202320242025
Revenue$2.0M$4.0M$5.0M$10.0M$5.0M
Operating Profit$-4.0M$-9.0M$-11.0M$-13.0M$-15.0M
Net Profit$-4.0M$-9.0M$-11.0M$-13.0M$-15.0M
EPS$0.00$-0.01$-0.01$-0.01$0.00
Op Margin-178.1%-250.9%-216.4%-129.3%-272.0%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$18.0M$23.0M$15.0M$21.0M$24.0M
Total Liabilities$1.0M$2.0M$2.0M$2.0M$6.0M
Cash$13.0M$16.0M$8.0M$9.0M$17.0M
Borrowings$0$0$0$0$3.0M

Latest News

Actinogen Medical’s Xanamem shows meaningful antidepressant activity in Phase 2 trial Proactive · Jul 24, 2026 Xanamem proof-of-concept trial demonstrating anti-depressant activity published in the British Journal of Psychiatry GlobeNewswire · Jul 20, 2026 Actinogen receives positive EMA scientific advice aligned with prior FDA guidance for its Alzheimer’s disease program GlobeNewswire · May 28, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-2.0M$-10.0M$-9.0M$-17.0M$-8.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$-1.0M$-1.0M$0$-1.0M$-1.0M
Net Cash Flow$8.0M$3.0M$-8.0M$1.0M$7.0M
Free Cash Flow$-2.0M$-10.0M$-9.0M$-17.0M$-8.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.07
EV / EBITDA-7.35
FCF Yield-10.79%
Quick Ratio4.19
Interest Coverage-110.71
Return 1Y-96.00%
Return 3Y-93.85%
Return 5Y—

Ownership

Insiders Held17.20%
Institutions Held2.01%
Institutions Float Held2.43%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
BSEMBioStem Technologies, Inc. $4.01 +4.59% -3.40 $68.11M 0.00%
CLTEFClara Technologies Corp. $0.06 -91.43% -23.94 $3.60M 0.00%
HBPCFHelix BioPharma Corp. $1.71 +0.00% -32.27 $130.61M 0.00%
INNMFAmplia Therapeutics Limited $0.11 +0.00% -8.38 $56.46M 0.00%
NICXFNicox S.A. $0.30 +0.00% -13.70 $29.17M 0.00%

About Actinogen Medical Limited

Actinogen Medical Limited is an Australian biotechnology firm specializing in the creation of treatments for neurological and neuropsychiatric conditions linked to abnormal brain cortisol levels. Their primary therapeutic candidate, Xanamem, functions as an inhibitor of the 11ß-HSD1 enzyme. Currently in Phase 2 clinical trials, Xanamem has shown the ability to engage its intended target within the central nervous system. Its development focuses on addressing Alzheimer's disease, cognitive impairment associated with depression, and the anxiety, sleep, and behavioral challenges seen in fragile X syndrome. Founded in 1999, the company, based in Sydney, Australia, operated as Actinogen Limited until its name change to Actinogen Medical Limited in November 2015.

Actinogen Medical Limited (ATGGF) stock trades at $0.00 with a market capitalization of $2.97M. The stock is valued at a price-to-earnings (P/E) ratio of -7.07, price-to-book of 0.38, price-to-sales of 0.40. Over the past 52 weeks the stock has ranged between $0.00 and $0.04, and currently trades 100.0% below its 52-week high.

On profitability, Actinogen Medical Limited generates a return on equity (ROE) of -110.77%, return on capital employed of -235.63%, an operating margin of -608.64%, a net profit margin of -243.22%.

Official website: www.actinogen.com.au

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides